The response rate using HMAs, such as AZA and decitabine (DEC), were reported to be higher in the subset of MDS patients with TET2 mutations compared to the TET2 wildtype, especially when the major disease clone is identified [86]. The gene discussed is TET2; the disease is myelodysplastic syndrome.